BriaCell Therapeutics

TILsRx

Proprietary platform designed to activate tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment; integrates T cell engagers and immune checkpoint modulators; multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets; focus areas include prostate, lung, breast, pancreatic, and ovarian cancers; early agents include antibodies to B7-H3

Targets: B7-H3

Bria-TILsRx

Quadrivalent multi-specific binding reagents designed as potent immune cell activators and/or immune checkpoint inhibitors; selectively target and destroy cancer cells while minimizing effects on normal cells; focus on immuno-oncology across multiple cancer types

Targets: B7-H3

Bria-OTS+

Personalized off-the-shelf immunotherapy platform for numerous cancer types including breast cancer, prostate cancer, lung cancer, and melanoma